<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373697</url>
  </required_header>
  <id_info>
    <org_study_id>TEU-IBU- 01-10</org_study_id>
    <nct_id>NCT01373697</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel</brief_title>
  <official_title>Clinical Multicenter, Phase III, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ibuprofen 50mg/g Gel in the Treatment of Patients With Muscle Pain, Joint, or Pain Caused by Sprains, Contusions, Tendinitis, or Myofascial Compared to Profenid ® 25mg/g. Gel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratório Teuto Brasileiro S/A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratório Teuto Brasileiro S/A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine that ibuprofen 50mg/g gel is effective and safety
      treating patients with muscle aches, joint pains or due to sprains, bruises, tendinitis or
      myofascial compared to Profenid 25mg/g gel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the efficacy of ibuprofen 50 mg/g gel in the
      treatment of patients with muscle, joint pain caused by sprains, contusions, tendinitis, or
      myofascial compared to Profenid 25mg/g gel.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical study evaluating the efficacy and safety of Ibuprofen 50mg / g gel in the treatment of patients with muscle pain, joint, or pain caused by sprains, contusions, tendinitis, or myofascial compared to Profenid ® 25mg / g gel. &quot;</measure>
    <time_frame>five days</time_frame>
    <description>To evaluate the efficacy of ibuprofen 50 mg / g gel in the treatment of patients with muscle aches, joint pains or due to sprains, bruises, tendinitis or myofascial compared with Profenid® Gel 25mg / g, will be used two methods. 1. the visual analog scale (VAS)and 2. investigator's opinion to measure before and after treatment comparing the decrease of the symptoms. The study will have 144 patients to be included with any sex or race, minimum age 12 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical study evaluating the tolerability of Ibuprofen 50mg / g gel in the treatment of patients with muscle pain, joint, or pain caused by sprains, contusions, tendinitis, or myofascial compared to Profenid ® 25mg / g gel. &quot;</measure>
    <time_frame>five days</time_frame>
    <description>To evaluate the tolerability of ibuprofen 50 mg / g gel in the treatment of patients with muscle aches, joint pains or due to sprains, bruises, tendinitis or myofascial compared with Profenid ® Gel 25mg / g will be use a measure using Naranjo algorithm to determinate the causality of the events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Muscular Atrophy</condition>
  <condition>Sprains</condition>
  <condition>Tendonitis</condition>
  <arm_group>
    <arm_group_label>Profenid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Profenid</intervention_name>
    <description>Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal</description>
    <arm_group_label>Profenid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes, of any race, aged 12 years;

          -  Ability to read, understand and sign the Informed Consent in the case of minors
             monitoring and consent of a parent;

          -  Complaint of clinical muscle pain, joint pain caused by sprains, contusions,
             tendonitis, or myofascial;

          -  Score more than 4 VAS symptom reviewed: Pain;

          -  Patients able to understand and follow the protocol of the trial.

          -  Patients with or without ligament injury ligament injury partial and incomplete

        Exclusion Criteria:

          -  Known hypersensitivity to components of the formula, both the medication and the
             comparative test;

          -  Hypersensitivity to acetylsalicylic acid;

          -  Hypersensitivity to ketoprofen, ibuprofen or other anti-inflammatory steroid;

          -  Hypersensitivity to acetaminophen;

          -  Skin changes in the pathological site of application, such as eczema or acne, or
             infected skin or wound;

          -  Pregnant or lactating women.

          -  Patients who require surgery or immobilization;

          -  Patients with fractures or ligament rupture;

          -  Patients taking anticoagulants;

          -  Patients with decompensated concomitant systemic diseases, such as diabetes,
             congenital or acquired blood disorders, convulsive disorders, autoimmune diseases,
             renal failure, severe infections, hormonal disorders and pulmonary disorders;

          -  Use of NSAIDs, corticosteroids or venotherapics, threads or any other form of
             administration;

          -  History of alcoholism or substance abuse;

          -  Conditions in the opinion of the investigator make the patient unsuitable to
             participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abel Pereira, investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>ABC School Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abel Pereira, researcher</last_name>
    <phone>11 55 4993-5459</phone>
    <email>abelpsjr@terra.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thabata Veiga, coordinator</last_name>
    <phone>11 55 4993-5459</phone>
    <email>thabataveiga.pesquisa@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ABC School of Medicine</name>
      <address>
        <city>São Paulo</city>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilberto Brandão, investigator</last_name>
      <phone>(11) 3825-5666</phone>
      <email>gilbertobrandao@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>PHC Pharma Consulting</name_title>
    <organization>Dagoberto Brandão</organization>
  </responsible_party>
  <keyword>Ibuprofen</keyword>
  <keyword>muscle pain</keyword>
  <keyword>sprains</keyword>
  <keyword>contusions</keyword>
  <keyword>tendonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Sprains and Strains</mesh_term>
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

